Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
12.37
-0.44 (-3.43%)
At close: May 14, 2025, 3:59 PM
12.45
0.65%
After-hours: May 14, 2025, 07:40 PM EDT
Viridian Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 300K | 300K | 1.8M | 3M | 735K | 7.37M |
| Collaboration Revenue Revenue Growth | 0.00% | -83.33% | -40.00% | +308.16% | -90.03% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 15.58M | 14.41M | 16.07M | 15.03M | 32.99M | 20.91M | 19.26M | 21.83M | 9.85M | 8.86M | 8.11M | 8.36M | 6.9M | 6.22M | 6.52M | 6.16M | 5.54M | 2.3M | 2.71M | 2.72M | 2.53M | 2.9M | 2.86M | 3.36M | 2.69M | 2.7M | 2.67M | 2.99M | 2.55M | 2.5M | 2.58M | 3.28M | 2.68M | 1.88M | 2.4M | 2.62M | 2.7M | 2.8M | 2.35M | 2.4M |
| Selling, General, and Administrative Revenue Growth | +8.16% | -10.32% | +6.93% | -54.46% | +57.78% | +8.55% | -11.76% | +121.54% | +11.21% | +9.29% | -3.00% | +21.13% | +10.93% | -4.63% | +5.89% | +11.25% | +140.84% | -15.04% | -0.62% | +7.46% | -12.56% | +1.44% | -14.89% | +24.56% | -0.04% | +1.05% | -10.77% | +17.35% | +1.84% | -3.06% | -21.33% | +22.33% | +42.66% | -21.54% | -8.44% | -3.22% | -3.39% | +19.01% | -1.88% | n/a |
| Research and Development Revenue | 71.84M | 69.16M | 56.19M | 40.94M | 38.56M | 30.39M | 40.08M | 50.74M | 39.32M | 22.12M | 21.71M | 17.75M | 22.39M | 8.12M | 12.56M | 13.81M | 15.25M | 3.11M | 3.84M | 6.1M | 8.42M | 9.03M | 8.6M | 8.75M | 8.23M | 7.4M | 8.38M | 6.41M | 5M | 5.02M | 5.49M | 4.12M | 21K | 226K | 334K | 307K | 456K | 253K | 194K | 100K |
| Research and Development Revenue Growth | +3.87% | +23.07% | +37.24% | +6.19% | +26.89% | -24.19% | -21.00% | +29.05% | +77.75% | +1.87% | +22.35% | -20.76% | +175.75% | -35.37% | -8.99% | -9.49% | +390.32% | -18.90% | -37.15% | -27.49% | -6.76% | +4.98% | -1.74% | +6.28% | +11.29% | -11.65% | +30.59% | +28.31% | -0.40% | -8.55% | +33.18% | +19519.05% | -90.71% | -32.34% | +8.79% | -32.68% | +80.24% | +30.41% | +94.00% | n/a |